Serum

Serum institute seeks permission to manufacture Sputnik V vaccine in India

SII said it will be able to manufacture and supply 10 crore Covishield doses in June while also manufacturing Novavax.

Serum Institute promises GOI it will supply 9-10 crore Covishield doses in June

Sespite the pandemic, SII said they have increased production capacity from 6.5 crore doses in May.

ICMR to conduct survey examining effectiveness of COVAXIN, COVISHIELD in preventing COVID-19

This first of its kind study is expected to be undertaken from next week, said Dr Tarun Bhatnagar, senior ICMR scientist.

COVID-19 vaccine: US to send 'urgently required' raw material to manufacture Covishield in India

The Biden administration had earlier come under criticism from several quarters for not releasing surplus COVID-19 vaccines to India, which is experiencing its worst-ever public health crisis

Serum institute begins Covovax clinical trials in India, vaccine may launch by September

The development and commercialisation pact between Novavax and SII excludes major upper-middle and high-income countries as they retain the rights

COVID-19 vaccination centers in Delhi has been reduced from 89 to 75

India's drugs regulator has approved Oxford COVID-19 vaccine Covishield, manufactured by the Serum Institute, and indigenously developed Covaxin of Bharat Biotech for restricted emergency use in the country.

Govt needs to protect vaccine manufacturers against all lawsuits, says SII CEO Adar Poonawalla

Last month, SII had rejected allegations of serious side-effects made by a participant in the Covishield vaccine trial in Chennai. The man had also sought Rs 5 crore compensation

Delhi's COVID cases continue to spike, SII completes phase-3 enrollment; country's tally at 86.83 lakh

The health ministry highlighted that 78 percent of the new cases were from 10 states and Union Territories (UTs) with Delhi continuing to register the highest single-day infections

Serum to apply for licence to manufacture Oxford vaccine in a week, says CEO Adar Poonawalla

Serum Institute of India, the largest vaccine manufacturer in the world, has been chosen by Oxford and its partner AstraZeneca to manufacture the vaccine once it gets ready.